Article record

特发性肺纤维化患者临床队列中的合并症：系统综述与荟萃分析

Comorbidities in clinical cohorts of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.

综述 Meta鼻科IF 11.5Q1

文献信息

PMID	42716548
原文	在 PubMed 查看原文 ↗
发表日期	2026
作者	Marcus C H Leong 查看其他 8 位作者 Seema Green；Mingkun Guan；Tyson M Walters；Emma Marshall；Chunbouy Sok；Nicole S L Goh；Christopher J Ryerson；Yet H Khor
作者单位	Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Australia. 查看其他 7 条单位信息 Faculty of Medicine, University of Melbourne, Melbourne, Australia.；Respiratory Research@Alfred, School of Translational Medicine, Monash University, Melbourne, Australia.；Department of General Medicine, Alfred Health, Melbourne, Australia.；Institute for Breathing and Sleep, Heidelberg, Australia.；Department of Medicine, University of British Columbia, Vancouver, BC, Canada.；Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada.；Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Australia yet.khor@monash.edu.
期刊	European respiratory review : an official journal of the European Respiratory Society
SCI 分区	Q1
IF	11.5
研究类型	综述 Meta · 临床
所属专科	鼻科

中文摘要

背景： 合并症可影响特发性肺纤维化（IPF）患者的治疗决策和健康结局。本系统综述与荟萃分析评估了IPF患者临床队列中合并症的类型和患病率，以及它们对健康结局的影响。
方法： 检索了Ovid MEDLINE和Embase，截止至2024年8月，纳入符合条件的观察性研究，要求至少100名成人IPF患者且报告至少一种合并症。对合并症患病率进行了荟萃分析，并对合并症与健康结局之间的关联进行了叙述性综合。
结果： 共纳入251项研究（n=606 398名参与者）。常见合并症包括系统性高血压（合并患病率39%，95%置信区间（CI）34-44%）、血脂异常（30%，95% CI 20-38%）、胃食管反流病（27%，95% CI 23-31%）、食管裂孔疝（20%，95% CI 9-33%）、超重/肥胖（22%，95% CI 18-27%）、糖尿病（21%，95% CI 19-23%）、缺血性心脏病（20%，95% CI 17-23%）和心力衰竭（15%，95% CI 13-18%）。很少有研究评估合并症与健康相关生活质量或IPF疾病进展之间的关系。肺癌是唯一与IPF患者短期和长期死亡率增加 consistently 相关的合并症。
结论： 多种合并症影响临床遇到的IPF患者，其中许多合并症的患病率高于临床试验队列中报告的水平。这凸显了在IPF管理中需要个性化护理。不同合并症与健康结局之间的关系值得未来研究，以更好地指导针对性筛查和管理。

英文摘要

BACKGROUND: Comorbidities can influence treatment decisions and health outcomes in patients with idiopathic pulmonary fibrosis (IPF). This systematic review and meta-analysis evaluated the types and prevalence of comorbidities, as well as their impact on health outcomes, in clinical cohorts of patients with IPF.
METHODS: Ovid MEDLINE and Embase were searched up to August 2024 for eligible observational studies with ≥100 adults with IPF that reported at least one comorbidity. Meta-analyses were performed for comorbidity prevalence, with associations between comorbidities and health outcomes narratively synthesised.
RESULTS: A total of 251 studies (n=606 398 participants) were included. Common comorbidities were systemic hypertension (pooled prevalence 39%, 95% confidence interval (CI) 34-44%), dyslipidaemia (30%, 95% CI 20-38%), gastro-oesophageal reflux disease (27%, 95% CI 23-31%), hiatus hernia (20%, 95% CI 9-33%), overweight/obesity (22%, 95% CI 18-27%), diabetes mellitus (21%, 95% CI 19-23%), ischaemic heart disease (20%, 95% CI 17-23%) and heart failure (15%, 95% CI 13-18%). Few studies evaluated the relationships between comorbidities and health-related quality of life or IPF disease progression. Lung cancer was the only comorbidity that was consistently associated with increased short-term and long-term mortality in patients with IPF.
CONCLUSIONS: A wide variety of comorbidities affect clinically encountered patients with IPF, with many having higher prevalence rates than those reported in clinical trial cohorts. This highlights the need for personalised care in the management of IPF. The relationships between different comorbidities and health outcomes warrant future studies to better inform targeted screening and management.